Compare DexCom, Inc. (DXCM) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Toyota Motor Corp — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Toyota Motor Corp trades at $185.3 (market cap $217.38B). The key difference: Toyota Motor Corp is far larger — about 6.8× DexCom, Inc.'s market cap, and Toyota Motor Corp pays a 3.37% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Toyota Motor Corp for 116 Days on average.
| DXCM | TM | |
|---|---|---|
Market Cap | $31.86B | $217.38B |
Volume | 3,607,070 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $248.29 |
52-Week Low | $54.84 | $166.50 |
Typical Hold Time | 62 Days | 116 Days |
Enterprise Value | $31.32B | $410.96B |
Dividend Yield | — | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Toyota Motor (TM) trades at $186.00, up 1.69% today, with a bearish technical signal but strong fundamentals. The stock shows attractive valuation ratios, including a P/E of 8.38 and P/B of 0.93, and has beaten EPS estimates in recent quarters. Recent news highlights U.S. sales growth and electrification efforts, though production declines in China and floods in Thailand pose challenges. Cash flow turned negative in 2025 but is projected to rebound in 2026.
TM presents a value opportunity with low multiples and consistent profitability, but near-term headwinds from global sales softness and supply chain disruptions warrant caution. Analyst consensus is mixed, with 37.5% buy ratings versus 62.5% hold, reflecting balanced optimism and patience. The stock's outlook hinges on execution in electrification and recovery in key markets like China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
